One of the most researched cosmetic peptides — stimulates collagen synthesis and reduces wrinkle depth with clinical evidence.
Matrixyl (palmitoyl pentapeptide-4, or Pal-KTTKS) is a lipopeptide consisting of the pentapeptide KTTKS (Lys-Thr-Thr-Lys-Ser) conjugated to a palmitoyl (C16 fatty acid) chain. The KTTKS sequence is a fragment of type I procollagen that acts as a matrikine — a matrix-derived signaling molecule that stimulates cells to produce new extracellular matrix components.
Developed by Sederma, Matrixyl was one of the first cosmetic peptides with peer-reviewed evidence supporting anti-aging claims. The palmitoyl modification improves skin penetration and cellular uptake compared to the naked KTTKS peptide. Once inside fibroblasts, the peptide fragment signals the cell to upregulate collagen I, collagen III, and fibronectin production.
Matrixyl 3000 is an advanced version combining palmitoyl tripeptide-1 and palmitoyl tetrapeptide-7, which work synergistically to stimulate collagen synthesis and reduce inflammation.
Published studies demonstrate Matrixyl reduces wrinkle depth by up to 68% with 4-month topical use — comparable to retinol in some studies. Increased collagen synthesis was confirmed by immunohistochemistry. The evidence base is stronger than for most cosmetic peptides.
Mechanism of action is well-supported: KTTKS fragments stimulate TGF-β signaling and collagen gene expression in dermal fibroblasts. The lipopeptide format enables sufficient skin penetration for biological activity.
📚 Key Reference: PMID: 15811073 (Matrixyl clinical study)
Excellent safety profile with decades of cosmetic use. No significant irritation. No photosensitivity (unlike retinoids). Suitable for sensitive skin. Not intended for injection.
Cosmetic ingredient. Not FDA-regulated as a drug. Widely available. One of the best-evidenced cosmetic peptides.